New drug cocktail aims to fight Hard-to-Treat throat cancer
NCT ID NCT07381699
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This Phase 2 trial tests a combination of two drugs—Becotatug vedotin (a targeted therapy) and Pucotenlimab (an immunotherapy)—as a first treatment for people whose nasopharyngeal cancer has come back or spread. The study will enroll 30 adults and measure how long the cancer stays under control. The goal is to see if this combo works better than current options.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Becotatug vedotin (a targeted drug) and Pucotenlimab (an immunotherapy drug)
- What this could lead to
- If successful, this combination could offer a new first-line treatment option for people with advanced nasopharyngeal carcinoma, potentially slowing disease progression.
- What could go wrong
- This is an early Phase 2 trial with only 30 participants, so results may not apply broadly. The drugs can cause side effects like infusion reactions or immune-related issues, and the combination may not improve outcomes over existing therapies.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NASOPHARYNGEAL CANCINOMA (NPC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a baking soda rinse tame radiation mouth sores?
- New drug duo aims to keep advanced nasopharyngeal cancer in check
- New surveillance strategy aims to catch residual cancer early in High-Risk nasopharyngeal carcinoma
- New combo strategy aims to catch and remove leftover cancer after radiation
- New combo injection targets Hard-to-Treat head and neck tumors
- New risk model may personalize Post-Chemo decisions for nasopharyngeal cancer